FDA Approves Moderna's mRNA Flu Vaccine in Breakthrough

The FDA approved MRNA Moderna's mFlusiva on August 5, marking the first mRNA-based seasonal flu vaccine to reach the US market.

The approval matters beyond one product launch: it is the first real-world test of whether mRNA technology, proven in COVID-19 vaccines, can work against a virus that mutates on a different schedule and where the existing standard of care is already effective and cheap. A strong showing could open the door to broader use of the platform across respiratory illnesses.

The approval covers adults 50 and older. The FDA granted standard approval for ages 50 to 64 and accelerated approval for those 65 and older, the latter contingent on results from a postmarketing study Moderna has already agreed to with regulators. In a trial covering people aged 50 to 64, mFlusiva produced 27% fewer confirmed flu cases than the current standard vaccine. Notably, the FDA had initially declined to review Moderna's application earlier this year before reversing course after the company committed to the additional study.

mFlusiva is expected to be available for the 2026-2027 respiratory illness season. Investors may want to watch early uptake among the 50-and-older population and whether the accelerated-approval postmarketing data, once available, supports broader use.

Related Stocks

• MRNA